Kyverna Therapeutics (KYTX) Interest & Investment Income (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Interest & Investment Income data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Interest & Investment Income fell 17.63% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $8.6 million (down 44.36% YoY), and the FY2025 full-year result was $9.1 million, down 40.79% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $2.3 million, up from $1.9 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $4.7 million in Q2 2024 and bottomed at $264000.0 in Q2 2023.
• The 4-year median for Interest & Investment Income is $2.3 million (2026), against an average of $2.2 million.
• The widest annual swing landed in 2024, when Interest & Investment Income soared 1678.03%; it then slumped 54.08% in 2025.
• A 4-year view of Interest & Investment Income shows it stood at $789000.0 in 2023, then surged by 353.11% to $3.6 million in 2024, then plunged by 46.71% to $1.9 million in 2025, then increased by 22.15% to $2.3 million in 2026.
• The last three Interest & Investment Income figures came in at $2.3 million (Q1 2026), $1.9 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.

Peer Comparison